Suppr超能文献

铂配合物作为抗癌剂。

Platinum complexes as anticancer agents.

作者信息

Kostova Irena

机构信息

Department of Chemistry, Faculty of Pharmacy, Medical University, 2 Dunav St., Sofia 1000, Bulgaria.

出版信息

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):1-22. doi: 10.2174/157489206775246458.

Abstract

The application of inorganic chemistry to medicine is a rapidly developing field, and novel therapeutic and diagnostic metal complexes are now having an impact on medical practice. Advances in biocoordination chemistry are crucial for improving the design of compounds to reduce toxic side effects and understand their mechanisms of action. Cisplatin, as one of the leading metal-based drugs, is widely used in the treatment of cancer. Significant side effects and drug resistance, however, have limited its clinical applications. Biological carriers conjugated to cisplatin analogs have improved specificity for tumor tissue, thereby reducing side effects and drug resistance. Platinum complexes with distinctively different DNA binding modes from that of cisplatin also exhibit promising pharmacological properties. This review focuses on recent advances in developing platinum anticancer agents with an emphasis on platinum coordination complexes.

摘要

无机化学在医学中的应用是一个快速发展的领域,新型治疗和诊断金属配合物正在对医疗实践产生影响。生物配位化学的进展对于改进化合物设计以减少毒副作用并了解其作用机制至关重要。顺铂作为主要的金属基药物之一,广泛用于癌症治疗。然而,显著的副作用和耐药性限制了其临床应用。与顺铂类似物共轭的生物载体对肿瘤组织具有更高的特异性,从而减少了副作用和耐药性。与顺铂具有明显不同DNA结合模式的铂配合物也表现出有前景的药理特性。本综述重点关注开发铂类抗癌药物的最新进展,尤其侧重于铂配位配合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验